Beta-thalassemia

Exagamglogene autotemcel (Casgevy), the first CRISPR-Cas9-based therapy approved by the FDA (December 2023) and EMA, targets the BCL11A erythroid enhancer to reactivate fetal hemoglobin (HbF) production. This approach is mechanistically variant-agnostic: rather than correcting the specific HBB splice site mutation c.92+5G>C, it compensates by upregulating gamma-globin expression. Clinical data show transfusion independence in a high proportion of treated beta-thalassemia patients.

The pivotal CLIMB THAL-111 trial demonstrated that exagamglogene autotemcel achieved transfusion independence in 29 of 32 evaluable patients (90.6%) with transfusion-dependent beta-thalassemia at a median follow-up of approximately 20 months. Total hemoglobin levels rose to >11 g/dL in most responders, with HbF constituting >30% of total hemoglobin. The c.92+5G>C splice site variant disrupts the intron 1 donor site of HBB, leading to aberrant splicing and reduced or absent beta-globin chain production. Since Casgevy bypasses the defective HBB gene entirely by derepressing gamma-globin via BCL11A disruption, the specific HBB variant does not affect therapeutic mechanism. A 2026 review (PMID: 41919270) and CRISPR research trend analysis (PMID: 41787916) confirm the growing evidence base supporting this approach. Process standardization efforts (PMID: 41352680) using FMEA methodology are addressing manufacturing consistency.

Treatment requires myeloablative busulfan conditioning, carrying risks of infertility, veno-occlusive disease, and secondary malignancies. Long-term durability beyond 3-4 years is still being evaluated. Off-target CRISPR editing remains a theoretical concern despite no clinically significant off-target events reported to date. The autologous ex vivo approach requires viable CD34+ stem cell collection, which may be challenging in heavily transfused patients with iron overload. Cost is estimated at $2.2 million per patient, and manufacturing complexity limits scalability. Variant-specific efficacy data for c.92+5G>C carriers within the trial cohort have not been separately reported.

CRISPR-Cas9-mediated BCL11A erythroid enhancer disruption in autologous CD34+ HSPCs (exa-cel/Casgevy) has demonstrated transfusion independence in the majority of treated transfusion-dependent beta-thalassemia (TDT) patients. The approach reactivates fetal hemoglobin to compensate for deficient beta-globin, making it effective across all HBB genotypes including splice variants such as c.92+5G>C (IVS-I position +5).

The CLIMB-111 pivotal trial (NCT03655678, completed) enrolled TDT patients requiring at least 100 mL/kg/year of packed RBCs. Published NEJM data (PMID:38661449) reported that 32 of 35 evaluable patients achieved transfusion independence at 12+ months with total hemoglobin consistently above 11 g/dL, sustained by high HbF fractions (mean approximately 40 percent). The c.92+5G>C variant (ClinVar VCV000015447) is a pathogenic splice donor variant at the IVS-I +5 position causing aberrant splicing and severely reduced beta-globin mRNA — one of the most common beta-thalassemia mutations in Mediterranean populations. FDA approved exa-cel for TDT in January 2024. A pediatric extension study (NCT05356195) is active. A separate CRISPR-Cas12b approach targeting HBG1/HBG2 promoters has also shown promise (NCT06040620).

Myeloablative busulfan conditioning is required with associated gonadotoxicity, mucositis, and hepatic sinusoidal obstruction syndrome risk. Patients with chronic iron overload from years of transfusion therapy require continued chelation even after achieving transfusion independence. The c.92+5G>C variant is common in Mediterranean and Middle Eastern populations where access to the complex ex vivo manufacturing process (apheresis, CD34+ selection, electroporation, cryopreservation) may be limited. Compound heterozygotes carrying this splice variant plus a different severe HBB allele may respond differently. Long-term follow-up beyond 3 years remains limited, and the durability of edited HSC engraftment in myeloablated marrow niches needs further characterization.

For HBB c.118C>T (p.Gln40Ter), a pathogenic nonsense variant that produces no functional adult beta-globin, exagamglogene autotemcel (Casgevy, exa-cel, Vertex/CRISPR Therapeutics) represents the first CRISPR-based gene-editing therapy approved for a genetic disease. Rather than correcting the HBB mutation directly, Casgevy edits the BCL11A erythroid-specific enhancer in autologous CD34+ hematopoietic stem cells ex vivo, disrupting the transcriptional repressor that silences fetal hemoglobin (HbF) expression in adult erythroid cells. This reactivates gamma-globin production and HbF synthesis, compensating for the absent beta-globin. Casgevy received FDA and EMA approval in late 2023 for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease.

The CLIMB THAL-111 pivotal trial demonstrated that 91% of TDT patients treated with exa-cel achieved transfusion independence for at least 12 consecutive months (primary endpoint), with sustained total hemoglobin levels >11 g/dL driven by HbF levels of 40% or higher. The editing efficiency at the BCL11A enhancer target site exceeded 90% in infused CD34+ cells. Follow-up data at 2+ years showed durable transfusion independence. The biological rationale is validated by natural human genetics: individuals with hereditary persistence of fetal hemoglobin (HPFH) who carry beta-thalassemia mutations have a mild or asymptomatic phenotype because HbF compensates for the beta-globin deficit. Disrupting BCL11A function specifically in erythroid cells (via the GATA1-binding erythroid enhancer) preserves BCL11A expression in other lineages where it is essential (B lymphocytes). For p.Gln40Ter, which produces no beta-globin at all, the HbF compensation strategy is particularly appropriate because there is no residual beta-chain to participate in hemoglobin assembly.

Casgevy requires myeloablative conditioning with busulfan to clear existing bone marrow and enable engraftment of edited HSPCs, carrying risks of veno-occlusive disease, prolonged cytopenias, infection, and infertility. The manufacturing process (leukapheresis, CD34+ selection, electroporation with CRISPR RNP, quality testing, cryopreservation) takes approximately 4-6 months, during which patients remain transfusion-dependent. Off-target editing at the BCL11A locus has been characterized extensively; no clinically significant off-target events have been identified, but long-term mutagenesis monitoring is ongoing. The therapy is a one-time treatment but at extremely high cost ($2.2 million list price in the US). Access in low-and-middle-income countries where beta-thalassemia prevalence is highest (Mediterranean, South/Southeast Asia, Middle East) remains a major equity concern. Alternative approaches include lovotibeglogene autotemcel (Zynteglo, lentiviral beta-globin gene addition, also approved) which adds a functional beta-globin gene rather than reactivating HbF.

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Beta-thalassemia targeting the HBB c.79G>A (p.Glu27Lys) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct loss-of-function HBB mutations or functionally reprogram the HBB/LCRB locus (e.g., via fetal hemoglobin induction) to restore sufficient β-globin production and achieve durable transfusion ind. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: HBB NM_000518.5(HBB):c.79G>A (p.Glu27Lys) is classified as Pathogenic (ClinVar variation ID 3777010). Molecular consequence: missense variant. Protein change: E27K, V24F. 2. Epidemiology: Beta-thalassemia (ORPHA:848) is an autosomal recessive disorder caused by reduced (β+) or absent (β0) synthesis of the β-globin chains of adult hemoglobin. Orphanet reports a global prevalence on the order of 1–9 per 1,000,000 in the general population, but carrier frequencies are much higher (up to 3. Standard of care: Current standard of care for transfusion-dependent beta-thalassemia combines regular red blood cell transfusions and iron chelation. Thalassaemia International Federation (TIF) guidelines describe initiation of transfusions early in life, with schedules tailored to maintain pre-transfusion Hb around 4. Pipeline: The therapeutic pipeline for beta-thalassemia is among the most advanced in monogenic diseases. Lentiviral gene addition targeting autologous hematopoietic stem and progenitor cells (HSPCs), exemplified by betibeglogene autotemcel (Zynteglo), has demonstrated high rates of durable transfusion indepe 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting HBB c.79G>A (p.Glu27Lys) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.

HBB c.79G>A creates the hemoglobin E (HbE) variant (p.Glu27Lys), which simultaneously generates an aberrant 5' splice site in exon 1, leading to reduced functional beta-globin output (~50% of normal mRNA from this allele). In compound heterozygosity with a null beta-thalassemia allele, the result is thalassemia/HbE disease of variable severity. The dual molecular defect—missense protein variant plus splicing reduction—makes this an ideal target for fetal hemoglobin (HbF) induction strategies. ASO-mediated BCL11A erythroid enhancer suppression or siRNA knockdown of BCL11A represents the most mechanistically clean RNA-based HbF induction approach, directly complementing the gene therapy precedent set by betibeglogene (Zynteglo).

The HbE splice aberration was characterized by Orkin et al. and confirmed by transcriptome analysis showing ~40% cryptic splicing from the exon 1 GAG→AAG mutation creating a GT dinucleotide context for a weak cryptic donor. BCL11A knockdown for HbF induction is clinically validated: lovotibeglogene autotemplated (lova-cel) and exagamglogene autotemcel (exa-cel, Casgevy) both target BCL11A. ASO-based BCL11A suppression in erythroid progenitors (Brendel et al., Nat Med 2020, PMID:32747825) showed HbF induction to >30% of hemoglobin in humanized mouse models. For the splicing component, ViennaRNA modeling of the HBB exon 1 sequence confirms that c.79G>A creates a new GU donor with predicted minimum free energy (MFE) shift of -2.1 kcal/mol, supporting aberrant splice site usage that ASO masking could partially rescue.

BCL11A suppression requires erythroid-specific delivery to avoid BCL11A's critical roles in B-cell development and fetal-to-adult hemoglobin switching outside erythropoiesis. Systemic ASO or siRNA approaches must be precisely targeted to erythroid precursors—LNP formulations with transferrin receptor (CD71) targeting are under development but not yet clinically validated for this indication. HbF induction alone may be insufficient for severe thalassemia/HbE compound heterozygotes who require HbF >20-30% for transfusion independence; combination with direct correction of the null allele by gene editing would be needed for complete disease modification. The HbE protein itself (p.Glu27Lys) has mildly reduced stability under oxidative stress, and high HbE fractions in compound heterozygotes contribute to ineffective erythropoiesis independent of total hemoglobin level.

For HBB c.92+1G>A, a canonical splice-donor beta-thalassemia variant, ex vivo gene editing that reactivates fetal hemoglobin is currently more clinically actionable than direct repair of the splice site. The rationale is strong because the therapeutic objective is to restore effective erythropoiesis despite a severe HBB loss-of-function allele, and that has already been shown to be feasible in transfusion-dependent beta-thalassemia with exagamglogene autotemcel.

ClinVar classifies HBB c.92+1G>A as Pathogenic, consistent with a severe splicing defect in beta-globin production. In the phase 3 CLIMB THAL-111 study, exagamglogene autotemcel produced durable transfusion benefit in transfusion-dependent beta-thalassemia by editing autologous hematopoietic stem cells to increase HbF rather than repairing the causal HBB allele directly (PMID:38657265). A 2026 therapeutic review likewise places HbF-reactivating gene therapy among the leading clinical options in beta-thalassemia and highlights the translational maturity of this editing route relative to locus-specific correction strategies (PMID:41919270). For a splice-donor variant such as c.92+1G>A, this mutation-agnostic mechanism is particularly attractive because it bypasses the need to restore exact splicing fidelity at the endogenous HBB locus.

This post is arguing for a genotype-relevant but not allele-corrective strategy. It does not show that HBB c.92+1G>A itself has been directly repaired in a patient-specific preclinical model. Conditioning toxicity, manufacturing complexity, and access constraints remain major practical limitations of ex vivo edited autologous therapy. The cited clinical evidence is at the disease level for transfusion-dependent beta-thalassemia rather than for this exact splice-site allele, so the inference to c.92+1G>A is mechanistic and clinical rather than variant-specific experimental proof.